

1 **Epidemiology and aetiology of moderate to severe diarrhoea in hospitalised HIV-infected patients**  
2 **≥5 years old in South Africa, 2018-2021: a case-control analysis**

3 **Authors and affiliations**

4 Siobhan L. Johnstone<sup>1,2</sup>, Linda Erasmus<sup>1</sup>, Juno Thomas<sup>1</sup>, Michelle J. Groome<sup>3,4</sup>, Nicolette M. du  
5 Plessis<sup>5</sup>, Theunis Avenant<sup>5</sup>, Maryke de Villiers<sup>6</sup>, Nicola A. Page<sup>1,7</sup>

6 <sup>1</sup>Center for Enteric Diseases, National Institute for Communicable Diseases, a division of the National  
7 Health Laboratory Service (NHLS), Johannesburg, South Africa; <sup>2</sup>School of Public Health, Faculty of  
8 Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; <sup>3</sup>Division of Public  
9 Health Surveillance and Response, National Institute for Communicable Diseases, a division of the  
10 National Health Laboratory Service (NHLS), Johannesburg, South Africa; <sup>4</sup>School of Pathology,  
11 Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa;  
12 <sup>5</sup>Department of Paediatrics, Kalafong Provincial Tertiary Hospital, Faculty of Health Sciences,  
13 University of Pretoria, Pretoria 0001, South Africa; <sup>6</sup>Department of Internal Medicine, Kalafong  
14 Provincial Tertiary Hospital, Faculty of Health Sciences, University of Pretoria, Pretoria 0001, South  
15 Africa; <sup>7</sup>Department of Medical Virology, Faculty of Health Sciences, University of Pretoria, Private  
16 Bag X323, Arcadia, 0007;

17 Corresponding author: Siobhan L. Johnstone; [siobhanj@nicd.ac.za](mailto:siobhanj@nicd.ac.za); [siobhanjsa@gmail.com](mailto:siobhanjsa@gmail.com); (+27)  
18 73 332 7905

19 Short title: Aetiology of diarrhoea in hospitalised HIV-infected patients

20 Key words: Diarrhoea, diagnostics, aetiology, HIV, South Africa

21 Authors' contributions

22 S.L.J, N.A.P, M.J.G, L.E and J.T conceptualised and designed the study. S.L.J, N.A.P, N.D., T.A. and

23 M.dV completed and managed fieldwork and data collection. S.L.J, N.A.P, M.J.G, L.E and J.T acquired,

24 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**  
analysed and interpreted the data. S.L.J drafted the work. All authors reviewed the manuscript.

25 Abstract

26 Diarrhoea is a recognised complication of HIV-infection, yet there are limited local aetiological data  
27 in this high-risk group. These data are important for informing public health interventions and  
28 updating diagnostic and treatment guidelines. This study aimed to determine the pathogenic causes  
29 for diarrhoeal admissions in HIV-infected patients compared to hospital controls between July 2018  
30 and November 2021.

31 Admitted diarrhoeal cases (n=243) and non-diarrhoeal hospital controls (n=101) ≥5 years of age  
32 were enrolled at Kalafong, Mapulaneng and Matikwana hospitals. Stool specimens/rectal swabs  
33 were collected and pathogen screening performed on multiple platforms. Differences in pathogen  
34 detections between cases and controls, stratified by HIV status, were investigated.

35 The majority (n=164, 67.5%) of diarrhoeal cases with known HIV status were HIV-infected.  
36 Pathogens could be detected in 66.3% (n=228) of specimens, with significantly higher detection in  
37 cases compared to controls (72.8% versus 50.5%,  $p<0.001$ ). Amongst HIV-infected participants,  
38 prevalence of *Cystoisospora* spp. was significantly higher in cases than controls (17.7% versus 0.0%,  
39  $p=0.028$ ), while *Schistosoma* was detected more often in controls than cases (17.4% versus 2.4%,  
40  $p=0.009$ ). Amongst the HIV-uninfected participants, prevalence of *Shigella* spp., *Salmonella* spp. and  
41 *Helicobacter pylori* was significantly higher in cases compared to controls (36.7% versus 12.0%,  
42  $p=0.002$ ; 11.4% versus 0.0%,  $p=0.012$ ; 10.1% versus 0.0%,  $p=0.023$ ).

43 Diarrhoeal aetiology differed by HIV status, with *Shigella* spp. (36.7%) and *Salmonella* spp. (11.4%)  
44 having the highest prevalence amongst HIV-uninfected cases and *Shigella* spp. (18.3%),  
45 *Cystoisospora* (17.7%), and *Cryptosporidium* spp. (15.9%) having the highest prevalence amongst  
46 HIV-infected cases. These differences should be considered for the development of diagnostic and  
47 treatment guidelines.

48

## 49 Introduction

50 Diarrhoeal diseases pose a significant health burden across the globe, causing over 1.6 million deaths  
51 annually amongst all ages<sup>1</sup>. The majority of these deaths occur in low- and middle-income countries  
52 (LMICs), specifically in south Asia and Sub-Saharan Africa (SSA)<sup>1</sup>. Despite a decrease in global  
53 diarrhoeal mortality rates over the past two decades, decreases have not been uniform across age  
54 groups or settings<sup>2</sup>. Unsafe water, poor sanitation and hygiene (WaSH)<sup>1</sup>, as well as malnutrition and  
55 compromised immunity<sup>3</sup> are the main risk factors associated with diarrhoeal morbidity and  
56 mortality. Other risk factors identified in LMICs include residence in a slum, use of communal toilets  
57 and exposure to animals<sup>4</sup>. Children under the age of 5 years are at the highest risk, however there is  
58 a significant burden in older age groups, specifically in LMICs<sup>1,5</sup>. Despite global improvements in  
59 WaSH<sup>6</sup>, much of the remaining burden of diarrhoeal disease may be attributed to foodborne  
60 pathogens<sup>7</sup>. Food safety is of specific concern in LMICs where there is increased consumption of  
61 unsafe foods, use of effluent in agriculture and changes in food distribution networks with bulk  
62 production and increased distance between production and consumption as well as large, often  
63 poorly regulated, informal sectors<sup>7</sup>.

64 Studies from high-income countries (HICs) have shown the majority of diarrhoeal diseases in adults  
65 seeking healthcare to be due to *Campylobacter* spp., *Salmonella* spp., norovirus and rotavirus<sup>8,9</sup>.  
66 Aetiology differs in SSA, with a meta-analysis amongst all ages identifying the main causative  
67 pathogens as *Escherichia coli*, *Cryptosporidium*, *Cyclospora*, *Entamoeba* and *Shigella* spp.<sup>10</sup> There are  
68 several reasons for these differences in aetiology including different exposures and risk factors  
69 associated with poorer living conditions and poor underlying health. One important consideration is  
70 the high prevalence of human immunodeficiency virus (HIV) in SSA<sup>11</sup>. HIV is a known risk factor for  
71 diarrhoea, with episodes in HIV-infected individuals more likely to be severe, prolonged and result in  
72 hospitalisation with higher mortality rates than in HIV-uninfected individuals<sup>12,13</sup>. The aetiology of  
73 diarrhoea in HIV-infected individuals is known to shift with HIV disease progression and treatment<sup>14</sup>.

74 During early disease stages, while CD4+ counts are high and viral loads low, diarrhoea is often  
75 related to HIV seroconversion. As disease progresses, diarrhoea is frequently caused by  
76 opportunistic pathogens related to decreased immune function<sup>14</sup>. These pathogens include bacterial  
77 infections, such as *Mycobacteria*, parasitic infections, such as *Cystoisospora belli*, *Cyclospora*,  
78 *Strongyloides*, *Cryptosporidia*, *Microsporidia* and viral infections, such as cytomegalovirus (CMV)<sup>14–16</sup>.  
79 Patients with low CD4+ cell counts are at increased risk for chronic diarrhoea<sup>4</sup> and polyparasitic  
80 infection<sup>17</sup>. The HIV infection itself may be responsible for a proportion of the pathogen-negative  
81 cases, through HIV enteropathy and permanent damage to the gastrointestinal mucosa<sup>18</sup>, as well as  
82 changes in gut microbial populations leading to dysbiosis<sup>19</sup>. Mucosal damage reduces small bowel  
83 villous surface area, causing diarrhoea through malabsorption<sup>20</sup> as well as defects to cellular and  
84 humoral defence mechanisms in the gastrointestinal tract<sup>21</sup>. Pathogen-negative cases associated  
85 with advanced HIV disease may also be related to gastrointestinal tract involvement by  
86 *Mycobacterium tuberculosis* and/or *avium*<sup>22</sup> which is difficult to diagnose. A Dutch study found that  
87 34% of diarrhoeal cases in untreated HIV-infected individuals could not be explained by a known  
88 causative agent, and hypothesized that these unexplained cases were due to the HIV-infection  
89 itself<sup>23</sup>. Initiation of antiretroviral treatment (ART), and accompanying increase in CD4+ cell count, is  
90 associated with a shift in the aetiology of diarrhoea from opportunistic infectious causes to non-  
91 infectious causes<sup>24</sup>. Data from both HICs and SSA show that although patients initiated on ART have  
92 significantly reduced diarrhoeal incidence compared with those not on treatment, the overall  
93 diarrhoeal incidence remains high<sup>18,25</sup>. A proportion of the remaining episodes in patients with well-  
94 controlled HIV may be drug-related<sup>18</sup>.

95 There are limited aetiological data on HIV-related diarrhoeal diseases in SSA, with the majority of  
96 published studies focusing on children under the age of five years, with available data in older  
97 children and adults being limited by diagnostic technology<sup>14</sup>. A review of laboratory records in  
98 Botswana indicated that only 14% of stool specimens submitted for routine diagnostic testing for all  
99 ages had a pathogen detected, of which 8% were bacteria and 6% parasites<sup>26</sup>. *Shigella* spp. and

100 *Salmonella* spp. were the most commonly detected bacteria while *Cystoisospora* spp. and  
101 *Cryptosporidium* spp. were the most commonly detected parasites. Viral testing was not done.  
102 Although HIV status was not available for the participants in this analysis, Botswana is a high HIV  
103 prevalence setting with an estimated 23.9% of the population between 15-49 years old being HIV-  
104 infected during the study time period<sup>26</sup>. Contrary to these findings, a longitudinal cohort study of  
105 Zambian adults with a 31% HIV seroprevalence (higher than the estimated population HIV  
106 seroprevalence of 22%) found that pathogens could be detected in 99% of stool samples collected  
107 (diarrhoeal and non-diarrhoeal patients combined), with *Cryptosporidium* spp., *Cystoisospora* spp.  
108 and *Citrobacter* spp. being significantly more common in HIV-infected than HIV-uninfected  
109 individuals<sup>5</sup>. They found that HIV-infected adults in the pre-ART era were 2.4 times as likely to suffer  
110 from diarrhoea than HIV-uninfected adults and that this increased risk lasted throughout the  
111 infection rather than being limited to those with low CD4+ cell counts<sup>5</sup>. Meta-analysis data indicates  
112 a high burden of *Cryptosporidium*, microsporidia and *Cystoisospora* in SSA specifically<sup>16</sup>. Another  
113 recent meta-analysis identified South Africa as having the highest global *Cryptosporidium* prevalence  
114 (57.0%, CI 95%: 24.4-84.5%), although they recognised that these estimates were based on limited  
115 data<sup>27</sup>. A study in rural South Africa found that 60% of patients suffering from chronic diarrhoea  
116 were HIV-infected and that the majority of these infections were due to *Campylobacter* spp. (20%),  
117 *Plesiomonas shigelloides* (17%), *Aeromonas* spp. (13%), *Shigella* spp. (10%), *Salmonella* spp. (10%)  
118 and *E. coli* spp. (10%)<sup>28</sup>. Testing did not include parasites or viruses and results were not stratified by  
119 ART status. Other studies in African children have identified HIV-infection as a significant risk factor  
120 for rotavirus infection<sup>13,29</sup>. Very few studies in SSA in adults included screening for viruses, despite  
121 data from HICs showing that viruses (specifically norovirus and rotavirus) were responsible for as  
122 much as 44% of diarrhoea in adults presenting to emergency departments<sup>9</sup>. Patients with advanced  
123 HIV are at increased risk for diarrhoea due to CMV infection<sup>30</sup>. As CMV is mainly diagnosed on  
124 endoscopic biopsy<sup>31</sup>, prevalence is likely underestimated.

125 South Africa currently has the highest HIV burden in the world, representing 19% of the global HIV-  
126 infected population<sup>32</sup>. It is estimated that 86% of HIV-infected adults in South Africa have been  
127 diagnosed, with 57% of these on ART (50.8% - 72.7% by province)<sup>33</sup>. Women, elderly patients, those  
128 with inadequate access to WaSH facilities and those not yet initiated on ART, have the highest risk  
129 for developing diarrhoea amongst HIV-infected South Africans<sup>34</sup>. The majority of data on HIV-related  
130 diarrhoea comes from HICs with low HIV prevalence<sup>14</sup>. Since diarrhoeal aetiology is likely to vary  
131 between settings<sup>35</sup>, there is a need for more targeted epidemiological studies<sup>18</sup>, specifically in LMICs  
132 with high HIV prevalence. There are few studies in HIV-infected populations which investigate a  
133 comprehensive range of pathogens or infections with multiple pathogens<sup>19</sup>. These data are  
134 important for informing public health interventions and updating diagnostic and treatment  
135 guidelines, especially since treatment is often based on guidelines rather than individual patient  
136 diagnostics<sup>36</sup>. This study aimed to determine the pathogenic causes for diarrhoeal admissions in HIV-  
137 infected patients compared to controls without diarrhoea at three South African hospitals between  
138 July 2018 and November 2021.

139

## 140 Methods

### 141 *Case and control enrolment*

142 Patients of all ages hospitalised with diarrhoea were enrolled at Kalafong, Mapulaneng and  
143 Matikwana hospitals through the African Network for improved Diagnostics, Epidemiology and  
144 Management of common Infectious Agents (ANDEMIA)<sup>37</sup>. Kalafong Provincial Tertiary Hospital is  
145 based on the western outskirts of Pretoria (Gauteng Province) and serves the generally low-income  
146 communities residing in urban townships to the west of Pretoria<sup>38</sup>. The rural sites included  
147 Mapulaneng, a 180 bed district hospital, and Matikwana, a 250 bed regional hospital<sup>39</sup>, both located  
148 in Bushbuckridge district in Mpumalanga Province.

149 Cases were defined as patients admitted with diarrhoea (three or more loose or liquid stools over a  
150 24 hour period) for any duration. Unmatched controls were defined as individuals presenting to the  
151 hospital or clinic for reasons other than diarrhoea (vaccination clinic, orthopaedic or surgical wards),  
152 without gastrointestinal symptoms (vomiting or diarrhoea) in the past 3 weeks. The study was  
153 explained to patients fulfilling the study definition and an information leaflet provided. Written  
154 informed consent was signed by patients  $\geq 18$  years of age and by parents/guardians for patients  $< 18$   
155 years. An assent form was signed for patients between 7-17 years. Surveillance Officers completed  
156 investigation forms by interviewing the patient, parent/guardian and reviewing clinical notes and  
157 laboratory results where available. HIV status was determined from the clinical notes and available  
158 laboratory results. Stool specimens or rectal swabs were collected from both cases and controls.  
159 Patients were enrolled within 48 hours of admission to exclude nosocomial infections. Cases were  
160 enrolled from July 2018 to June 2021 and controls enrolled from October 2019 to November 2021.  
161 Cases and controls unable to provide specimens and patients  $< 5$  years old were excluded from this  
162 analysis.

### 163 *Laboratory testing*

164 Pathogen screening was performed on Fast-track Diagnostics (viral and bacterial gastroenteritis and  
165 stool parasite kits), Seegene Allplex (GI-Parasite and GI-Helminth(I) assays) as well as TaqMan Array  
166 Cards (TAC) (included pathogens indicated in Table S1). Monoplex PCR was used to determine final  
167 outcome where there were discrepant results between testing platforms for a specific target. Due to  
168 limited available TAC cards, cases with unknown HIV status were excluded from testing. Controls  
169 with unknown HIV status were included in the overall case-control analysis (since there were limited  
170 control specimens available) but were not included in the HIV specific case-control analysis.

### 171 *Data management and statistical analysis*

172 Results for CD4+ cell count were extracted from the National Health Laboratory Service (NHLS)  
173 database for HIV-infected cases and were categorised into three classes ( $< 200$  cells/ $\mu$ l; 200-500

174 cells/ $\mu$ l; >500 cells/ $\mu$ l). Only CD4+ cell count results within 12 months of the enrolment were  
175 included and where multiple results were available for a single patient, the results closest to the  
176 time of enrolment were used. Demographic and socioeconomic characteristics for cases and controls  
177 were compared. Clinical presentation for HIV-infected versus HIV-uninfected cases were compared.  
178 Pathogen detection amongst case and control specimens were compared, stratified by HIV status.  
179 Clinical presentation and pathogen detection for HIV-infected cases was compared between CD4+  
180 cell count categories and for ART and cotrimoxazole prophylaxis treatment. X<sup>2</sup>-test and Fisher's exact  
181 test were used for categorical variables and t-test for continuous variables. *P-values*<0.05 were  
182 considered to be statistically significant. Stata software (version 14) was used for all analyses.

### 183 *Ethical considerations*

184 The ANDEMIA study was approved by the Human Research Ethics Committee (Medical) of the  
185 University of the Witwatersrand (approval numbers M170403) and the University of Pretoria Faculty  
186 of Health Sciences Research Ethics Committee (approval number 101/2017). The HIV sub-analysis  
187 was approved by the Human Research Ethics Committee (Medical) of the University of the  
188 Witwatersrand (approval numbers M190663).

### 189 Results

#### 190 *Enrolment and patient characteristics*

191 A total of 378 specimens for patients  $\geq$ 5 years were collected during the study period, including 277  
192 cases and 101 controls (Figure 1). Amongst cases, 164 (59.2%) were HIV-infected, 79 (28.5%) were  
193 HIV-uninfected and 34 (12.3%) had unknown HIV status. Amongst controls, 23 (22.8%) were HIV-  
194 infected, 50 (49.5%) were HIV-uninfected and 28 (27.7%) had unknown HIV status. Cases with  
195 unknown HIV status (n=34) were excluded (due to limited testing capacity), hence a total of 344  
196 specimens were included in the analysis.

197



198 Figure 1: Specimens included in the analysis

199 The median age of included patients was 34 years (IQR of 23-47), with cases being slightly older  
 200 (median 36; IQR 26-51) than controls (median 31; IQR 17-38) (Table 1). The majority of patients were  
 201 female (59.4%) and from the rural sites (67.4%), with proportionally more controls coming from the  
 202 rural site than cases (82.2% versus 61.3%,  $p < 0.001$ ). Cases and controls were similar with respect to  
 203 household crowding and dietary habits. Both cases and controls had good access to electric or gas  
 204 cookers (86.1%), refrigerators (88.4%) and improved WaSH (94.8% access to improved water source  
 205 and 96.4% access to private latrines/flush toilets). CD4+ cell counts were available for 99 (60.4%) of  
 206 the 164 HIV-infected cases. Eight (8.1%) had counts  $> 500$  cells/ $\mu$ l, 21 (21.2%) were between 200-500  
 207 cells/ $\mu$ l and the majority ( $n=70$ , 70.7%) had  $< 200$  cells/ $\mu$ l. Information regarding ART was available  
 208 for 156 (95.1%) of the HIV-infected cases, of which 130 (83.3%) were on treatment. Mean CD4+ cells  
 209 counts were similar between those on ART (229.23 cells/ $\mu$ l) and those not on ART (169.7 cells/ $\mu$ l),  
 210 ( $p=0.418$ ). Information regarding cotrimoxazole treatment was available for 151 HIV-infected  
 211 patients, of which 63 (41.7%) were on treatment.

212

213 Table 1: Comparison of patient characteristics for cases and controls

	<b>Total (n=344)</b>	<b>Cases (n=243)</b>	<b>Controls (n=101)</b>	<b>p-value</b>
<b>Age (years) – median (IQR)</b>	34 (23-47)	36 (26-51)	31 (17-38)	<b>&lt;0.001<sup>f</sup></b>
<b>Male</b>	129 (40.6%)	88 (36.2%)	41 (40.6%)	0.445
<b>Rural</b>	232 (67.4%)	149 (61.3%)	83 (82.2%)	<b>&lt;0.001</b>
<b>HIV-infected<sup>a</sup></b>	187/316 (59.2%)	164/243 (67.5%)	23/73 (31.5%)	<b>&lt;0.001</b>
<b>Education<sup>b</sup></b>				<b>0.002<sup>g</sup></b>
<b>None</b>	13/337 (3.9%)	10/237 (4.2%)	3/100 (3.0%)	
<b>&lt;= 6 years</b>	53/337 (15.7%)	47/237 (19.8%)	6/100 (6.0%)	
<b>7-10 years</b>	107/337 (31.8%)	78/237 (32.9%)	29/100 (29.0%)	
<b>&gt;10 years</b>	164/337 (48.7%)	102/237 (43.0%)	62/100 (62.0%)	
<b>Household crowding/people per room – mean (std. dev)</b>	2.0 (1.2)	2.0 (1.9)	2.0 (0.9)	0.733 <sup>f</sup>
<b>Electric or gas cooker</b>	296 (86.1%)	210 (86.4%)	86 (85.1%)	0.757
<b>Refrigerator</b>	289/327 (88.4%)	200/231 (86.6%)	89/96 (92.7%)	0.115

<b>Improved water source<sup>c</sup></b>	326 (94.8%)	229 (94.2%)	97 (96.0%)	0.603 <sup>§</sup>
<b>Treat drinking water<sup>d</sup></b>	45 (13.1%)	31 (12.8%)	14 (13.9%)	0.782
<b>Toilet type</b>				
<b>Private flush</b>	86/337 (25.5%)	62/241 (25.7%)	24/96 (25.0%)	0.604 <sup>§</sup>
<b>Private latrine</b>	239/337 (70.9%)	170/241 (70.5%)	69/96 (71.9%)	
<b>Communal flush</b>	8/337 (2.3%)	7/241 (2.9%)	1/96 (1.0%)	
<b>Communal latrine</b>	2/337 (0.6%)	1/241 (0.4%)	1/96 (1.0%)	
<b>Other</b>	2/337 (0.6%)	1/241 (0.4%)	1/96 (1.0%)	
<b>Dairy<sup>e</sup></b>	156 (45.4%)	107 (44.0%)	49 (48.5%)	0.447
<b>Deli meat<sup>e</sup></b>	103 (29.9%)	79 (32.5%)	24 (23.8%)	0.107
<b>Eggs<sup>e</sup></b>	183 (53.2%)	127 (52.3%)	56 (55.5%)	0.590

214 <sup>a</sup> For participants with known HIV status only; <sup>b</sup> highest level of education that the patient (or parent/caregiver  
 215 if patient is <15 years) has obtained; <sup>c</sup> piped water to an inside or outside tap (as opposed to river, rain or well  
 216 water or water from a truck); <sup>d</sup> by boiling or chemical treatment; <sup>e</sup> In the preceding 4 weeks; <sup>f</sup> t-test; <sup>§</sup> fisher's  
 217 exact test; denominators given when different to column headings due to missing data.

### 218 *Clinical presentation of cases*

219 HIV-infected cases were likely to experience symptoms for a longer duration before admission  
 220 (median of 5 days versus 2 days,  $p < 0.001$ ) and were more likely to have chronic or persistent  
 221 diarrhoea (8.5% versus 0.0%,  $p = 0.006$ ) than HIV-uninfected cases (Table 2). The most common  
 222 symptoms experienced by all cases were fatigue (182, 74.9%), weight loss (176, 72.4%), vomiting  
 223 (172, 70.8%), fever (168, 69.1%), abdominal pain (166, 68.3%) and nausea (165, 67.9%). HIV-infected  
 224 cases were more likely to suffer from weight loss (81.1% versus 54.4%,  $p < 0.001$ ) and nausea (72.0%  
 225 versus 59.5%,  $p = 0.051$ ), while HIV-uninfected cases were more likely to suffer from dysentery (15.2%  
 226 versus 4.3%,  $p = 0.003$ ).

227 Table 2: Clinical presentation of diarrhoeal cases

	<b>Total (n=243)</b>	<b>HIV-infected (n=164)</b>	<b>HIV-uninfected (n=79)</b>	<b>p-value</b>
<b>Duration of symptoms before admission (days) – median (IQR)</b>	4 (2-8)	5 (3-8)	2 (1-4)	<b>&lt;0.001<sup>d</sup></b>
<b>Chronic/persistent diarrhoea<sup>a</sup></b>	13 (5.4%)	13 (7.9%)	0 (0.0%)	<b>0.011<sup>e</sup></b>
<b>Fatigue</b>	182 (74.9%)	124 (75.6%)	58 (73.4%)	0.712
<b>Weight loss</b>	176 (72.4%)	133 (81.1%)	43 (54.4%)	<b>&lt;0.001</b>
<b>Vomiting</b>	172 (70.8%)	118 (72.0%)	54 (68.4%)	0.564
<b>Fever<sup>b</sup></b>	168 (69.1%)	113 (68.9%)	55 (69.6%)	0.910

<b>Abdominal pain</b>	166 (68.3%)	106 (64.6%)	60 (76.0%)	0.076
<b>Nausea</b>	165 (67.9%)	118 (72.0%)	47 (59.5%)	0.051
<b>Respiratory symptoms</b>	105 (43.2%)	77 (47.0%)	28 (35.4%)	0.090
<b>Headache</b>	100 (41.2%)	68 (41.5%)	32 (40.5%)	0.887
<b>Chills</b>	63 (25.9%)	48 (29.3%)	15 (19.0%)	0.087
<b>Arthralgia</b>	51 (21.0%)	38 (23.2%)	13 (16.5%)	0.229
<b>Dermatological symptoms</b>	31 (12.8%)	25 (15.2%)	6 (7.6%)	0.094
<b>Myalgia</b>	24 (10.0%)	16 (9.8%)	8 (10.1%)	0.928
<b>Dysentery<sup>c</sup></b>	19 (7.8%)	7 (4.3%)	12 (15.2%)	<b>0.003</b>
<b>Neurological symptoms</b>	10 (4.1%)	6 (3.7%)	4 (5.1%)	0.732 <sup>e</sup>
<b>Painful lymphadenopathy</b>	4 (1.7%)	3 (1.9%)	1 (1.3%)	>0.99 <sup>e</sup>

228 <sup>a</sup> diarrhoea for 28 days or longer; <sup>b</sup> current temperature of >38°C or history of fever in the past 10 days; <sup>c</sup>  
229 Dysentery defined as self-reported blood in the stool; <sup>d</sup> t-test; <sup>e</sup> fisher's exact test

### 230 Pathogen detection in specimens of cases and controls

231 Pathogens were detected in 66.3% (228) of specimens tested, with significantly higher detection in  
232 cases compared with controls (72.8% versus 50.5%,  $p < 0.001$ ; Table 3). Bacteria were more prevalent  
233 in cases compared with controls (50.2% versus 28.7%,  $p < 0.001$ ), specifically *Shigella* spp., *Salmonella*  
234 spp. and *Helicobacter pylori* (24.3% versus 10.9%,  $p = 0.005$ ; 8.6% versus 1.0%,  $p = 0.007$  and 8.6%  
235 versus 0.0%,  $p = 0.001$ , respectively). Detection of viruses was significantly higher in cases compared  
236 with controls (21.8% versus 10.9%,  $p = 0.018$ ), specifically for adenovirus (11.0% versus 4.0%,  
237  $p = 0.038$ ). Parasites were detected in 37.8% (130) of specimens tested, however, detection was not  
238 significantly higher in cases than controls (40.7% versus 30.7%,  $p = 0.080$ ) with the available sample  
239 size. Prevalence of *Cystoisospora*, *Cryptosporidium* spp. and *Enterocytozoon* spp. was significantly  
240 higher in cases than controls (11.9% versus 0.0%,  $p < 0.00$ ; 11.1% versus 3.0%,  $p = 0.012$ ; 4.5% versus  
241 0.0%,  $p = 0.038$ , respectively). *Blastocystis* and *Schistosoma* were more prevalent amongst controls  
242 than amongst cases (23.8% versus 10.3%,  $p = 0.001$ ; 6.9% versus 2.1%,  $p = 0.025$ , respectively). Cases  
243 were more likely than controls to have multiple pathogens detected (37.9% versus 22.8%,  $p = 0.007$ ).  
244 Amongst HIV-infected participants, *Cystoisospora* spp. prevalence was significantly higher in cases  
245 than in controls (17.7% versus 0.0%,  $p = 0.028$ ), while *Schistosoma* was detected more often in  
246 controls compared with cases (17.4% versus 2.4%,  $p = 0.009$ ). Amongst the HIV-uninfected

247 participants, *Shigella* spp., *Salmonella* spp. and *Helicobacter pylori* were more prevalent amongst  
248 cases than controls (36.7% versus 12.0%,  $p=0.002$ ; 11.4% versus 0.0%,  $p=0.012$ ; 10.1% versus 0.0%,  
249  $p=0.023$ ). Norovirus GII, *C. difficile*, *Campylobacter*, *Cystoisospora*, *Cryptosporidium* spp. and  
250 *Enterocytozoon* spp. were more prevalent amongst HIV-infected than HIV-uninfected participants  
251 (6.4% versus 1.6%,  $p=0.032$ ; 7.0% versus 0.8%,  $p=0.010$ ; 6.4% versus 0.8%,  $p=0.018$ ; 15.5% versus  
252 0.01%,  $p<0.001$ ; 15.0% versus 1.6%,  $p<0.001$ ; 5.4% versus 0.8%,  $p=0.031$ ). *Shigella* spp. and  
253 *Blastocystis* were more prevalent amongst HIV-uninfected than HIV-infected participants (27.1%  
254 versus 17.1%,  $p=0.032$ ; 25.6% versus 8.0%,  $p<0.001$ ). *Shigella* spp. (18.3%) and *Cystoisospora* (17.7%)  
255 were the most prevalent pathogens detected in HIV-infected diarrhoeal cases, while *Shigella* spp.  
256 (36.7%) and *Salmonella* spp. (11.4%) were the most prevalent pathogens in HIV-uninfected  
257 diarrhoeal cases. Although *Blastocystis* was prevalent in HIV-uninfected cases, it was not associated  
258 with diarrhoea as prevalence was significantly higher in HIV-uninfected controls (40.0% versus  
259 16.5%,  $p<0.001$ ).

260 Table 3: Pathogen detection in specimens of cases and controls, stratified by HIV-infection status

	Overall – n <sup>a</sup> (%)				HIV-infected – n <sup>a</sup> (%)				HIV-uninfected – n <sup>a</sup> (%)				p-value <sup>c</sup>
	Total (n=344)	Cases (n=243)	Controls (n=101)	p-value <sup>b</sup>	Total (n=187)	Cases (n=164)	Controls (n=23)	p-value <sup>b</sup>	Total (n=129)	Cases (n=79)	Controls (n=50)	p-value <sup>b</sup>	
<b>Any pathogen</b>	228 (66.3)	177 (72.8)	51 (50.5)	<b>&lt;0.001</b>	138 (73.8)	124 (75.6)	14 (60.9)	0.132	84 (65.1)	53 (67.1)	31 (62.0)	0.555	0.097
<b>Virus</b>	64 (18.6)	53 (21.8)	11 (10.9)	<b>0.018</b>	43 (22.1)	40 (24.4)	3 (13.0)	0.296 <sup>e</sup>	20 (15.5)	13 (16.5)	7 (14.0)	0.707	0.101
<b>Adenovirus</b>	31 (9.0)	27 (11.1)	4 (4.0)	<b>0.038<sup>e</sup></b>	20 (10.7)	19 (11.6)	1 (4.4)	0.476 <sup>e</sup>	10 (7.8)	8 (10.1)	2 (4.0)	0.314 <sup>e</sup>	0.380
<b>Adenovirus 40/41</b>	3 (0.9)	3 (1.2)	0 (0.0)	0.558 <sup>e</sup>	2 (1.1)	2 (1.2)	0 (0.0)	>0.99 <sup>e</sup>	1 (0.8)	1 (1.3)	0 (0.0)	>0.99 <sup>e</sup>	0.637 <sup>e</sup>
<b>Norovirus</b>	18 (5.2)	14 (5.8)	4 (4.0)	0.603 <sup>e</sup>	13 (7.0)	13 (7.9)	0 (0.0)	0.374 <sup>e</sup>	5 (3.9)	1 (1.3)	4 (8.0)	0.074 <sup>e</sup>	0.246
<b>Norovirus GI</b>	4 (1.2)	2 (0.8)	2 (2.0)	0.584 <sup>e</sup>	1 (0.5)	1 (0.6)	0 (0.0)	>0.99 <sup>e</sup>	3 (2.3)	1 (1.3)	2 (4.0)	0.559 <sup>e</sup>	0.308 <sup>e</sup>
<b>Norovirus GII</b>	14 (4.1)	12 (4.9)	2 (2.0)	0.248 <sup>e</sup>	12 (6.4)	12 (7.3)	0 (0.0)	0.367 <sup>e</sup>	2 (1.6)	0 (0.0)	2 (4.0)	0.148 <sup>e</sup>	0.032 <sup>e</sup>
<b>Enterovirus</b>	16 (4.7)	12 (4.9)	4 (4.0)	0.787 <sup>e</sup>	12 (6.4)	10 (6.1)	2 (8.7)	0.645 <sup>e</sup>	4 (3.1)	2 (2.5)	2 (4.0)	0.641 <sup>e</sup>	0.296 <sup>e</sup>
<b>CMV</b>	3 (0.9)	3 (1.2)	0 (0.0)	0.558 <sup>e</sup>	3 (1.6)	3 (1.8)	0 (0.0)	>0.99 <sup>e</sup>	0 (0.0)	0 (0.0)	0 (0.0)	-	0.273 <sup>e</sup>
<b>Astrovirus</b>	5 (1.5)	4 (1.7)	1 (1.0)	>0.99 <sup>e</sup>	3 (1.6)	3 (1.8)	0 (0.0)	>0.99 <sup>e</sup>	2 (1.6)	1 (1.3)	1 (2.0)	>0.99 <sup>e</sup>	>0.99 <sup>e</sup>
<b>Rotavirus</b>	2 (0.6)	2 (0.8)	0 (0.0)	>0.99 <sup>e</sup>	1 (0.5)	1 (0.6)	0 (0.0)	>0.99 <sup>e</sup>	1 (0.8)	1 (1.3)	0 (0.0)	1.000 <sup>e</sup>	>0.99 <sup>e</sup>
<b>Sapovirus</b>	1 (0.3)	1 (0.4)	0 (0.0)	>0.99 <sup>e</sup>	1 (0.5)	1 (0.6)	0 (0.0)	>0.99 <sup>e</sup>	0 (0.0)	0 (0.0)	0 (0.0)	-	>0.99 <sup>e</sup>
<b>&gt;1 virus detected</b>	9 (2.6)	7 (2.9)	2 (2.0)	>0.99 <sup>e</sup>	7 (3.7)	7 (4.3)	0 (0.0)	0.600 <sup>e</sup>	2 (1.6)	0 (0.0)	2 (4.0)	0.148 <sup>e</sup>	0.318 <sup>e</sup>
<b>Bacteria</b>	151 (48.9)	122 (50.2)	29 (28.7)	<b>&lt;0.001</b>	87 (46.5)	76 (46.3)	11 (47.8)	0.894	61 (47.3)	46 (58.2)	15 (30.0)	<b>0.002</b>	0.894
<b>Shigella spp.</b>	70 (20.4)	59 (24.3)	11 (10.9)	<b>0.005</b>	32 (17.1)	30 (18.3)	2 (8.7)	0.378 <sup>e</sup>	35 (27.1)	29 (36.7)	6 (12.0)	<b>0.002</b>	<b>0.032</b>
<b>Salmonella spp.</b>	22 (6.4)	21 (8.6)	1 (1.0)	<b>0.007<sup>e</sup></b>	13 (7.0)	12 (7.3)	1 (4.4)	>0.99 <sup>e</sup>	9 (7.0)	9 (11.4)	0 (0.0)	<b>0.012<sup>e</sup></b>	0.993
<b>C. difficile</b>	14 (4.1)	13 (5.4)	1 (1.0)	0.074 <sup>e</sup>	13 (7.0)	12 (7.3)	1 (4.4)	>0.99 <sup>e</sup>	1 (0.8)	1 (1.3)	0 (0.0)	>0.99 <sup>e</sup>	<b>0.010<sup>e</sup></b>
<b>Campylobacter</b>	13 (3.8)	12 (4.9)	1 (1.0)	0.119 <sup>e</sup>	12 (6.4)	12 (7.3)	0 (0.0)	0.367 <sup>e</sup>	1 (0.8)	0 (0.0)	1 (2.0)	0.388 <sup>e</sup>	<b>0.018<sup>e</sup></b>
<b>STEC</b>	2 (0.6)	0 (0.0)	2 (2.0)	0.086 <sup>e</sup>	0 (0.0)	0 (0.0)	0 (0.0)	-	2 (1.6)	0 (0.0)	2 (4.0)	0.148 <sup>e</sup>	0.166 <sup>e</sup>
<b>ETEC</b>	11 (3.2)	9 (3.7)	2 (2.0)	0.519 <sup>e</sup>	7 (3.7)	5 (3.1)	2 (8.7)	0.207 <sup>e</sup>	4 (3.1)	4 (5.1)	0 (0.0)	0.157 <sup>e</sup>	>0.99 <sup>e</sup>
<b>EPEC</b>	21 (6.1)	14 (5.8)	7 (6.9)	0.631	15 (8.0)	11 (6.7)	4 (17.4)	0.094 <sup>e</sup>	6 (4.7)	3 (3.8)	3 (6.0)	0.676 <sup>e</sup>	0.237
<b>EAEC</b>	41 (11.9)	28 (11.5)	13 (12.9)	0.725	25 (13.4)	20 (12.2)	5 (21.7)	0.208	14 (10.9)	8 (10.1)	6 (12.0)	0.739	0.504
<b>O157</b>	4 (1.2)	4 (1.7)	0 (0.0)	0.325 <sup>e</sup>	3 (1.6)	3 (1.8)	0 (0.0)	>0.99 <sup>e</sup>	1 (0.8)	1 (1.3)	0 (0.0)	>0.99 <sup>e</sup>	0.648 <sup>e</sup>
<b>Plesiomonas</b>	1 (0.3)	1 (0.4)	0 (0.0)	>0.99 <sup>e</sup>	1 (0.5)	1 (0.6)	0 (0.0)	>0.99 <sup>e</sup>	0 (0.0)	0 (0.0)	0 (0.0)	-	>0.99 <sup>e</sup>
<b>Helicobacter pylori</b>	21 (6.1)	21 (8.6)	0 (0.0)	<b>0.001<sup>e</sup></b>	13 (7.0)	13 (7.9)	0 (0.0)	0.374 <sup>e</sup>	8 (6.2)	8 (10.1)	0 (0.0)	<b>0.023<sup>e</sup></b>	>0.99

<b>&gt;1 bacteria detected</b>	45 (13.1)	37 (15.2)	8 (7.9)	0.067	23 (12.3)	20 (12.2)	3 (13.0)	>0.99 <sup>e</sup>	11 (8.5)	8 (10.1)	3 (6.0)	0.528 <sup>e</sup>	0.287
<b>Parasite<sup>d</sup></b>	130 (37.8)	99 (40.7)	31 (30.7)	0.080	85 (45.5)	78 (47.6)	7 (30.4)	0.122	43 (33.3)	21 (26.6)	22 (44.0)	0.042	<b>0.031</b>
<b><i>Cystoisospora</i></b>	29 (8.4)	29 (11.9)	0 (0.0)	<b>&lt;0.001<sup>e</sup></b>	29 (15.5)	20 (17.7)	0 (0.0)	<b>0.028<sup>e</sup></b>	0 (0.0)	0 (0.0)	0 (0.0)	-	<b>&lt;0.001<sup>e</sup></b>
<b><i>Cryptosporidium</i> spp.</b>	30 (8.7)	27 (11.1)	3 (3.0)	<b>0.012<sup>e</sup></b>	28 (15.0)	26 (15.9)	2 (8.7)	0.537 <sup>e</sup>	2 (1.6)	1 (1.3)	1 (2.0)	>0.99 <sup>e</sup>	<b>&lt;0.001<sup>e</sup></b>
<b><i>Blastocystis</i></b>	49 (14.2)	25 (10.3)	24 (23.8)	<b>0.001</b>	15 (8.0)	12 (7.3)	3 (13.0)	0.403 <sup>e</sup>	33 (25.6)	13 (16.5)	20 (40.0)	<b>0.003</b>	<b>&lt;0.001</b>
<b><i>Giardia</i> spp.</b>	12 (3.5)	9 (3.7)	3 (3.0)	>0.99 <sup>e</sup>	7 (3.7)	7 (4.3)	0 (0.0)	0.600 <sup>e</sup>	4 (3.1)	2 (2.5)	2 (4.0)	0.641 <sup>e</sup>	>0.99 <sup>e</sup>
<b><i>Enterocytozoon</i> spp.</b>	11 (3.2)	11 (4.5)	0 (0.0)	<b>0.038<sup>e</sup></b>	10 (5.4)	10 (6.1)	0 (0.0)	0.614 <sup>e</sup>	1 (0.8)	1 (1.3)	0 (0.0)	>0.99 <sup>e</sup>	<b>0.031<sup>e</sup></b>
<b><i>Schistosoma</i></b>	12 (3.5)	5 (2.1)	7 (6.9)	<b>0.025</b>	8 (4.3)	4 (2.4)	4 (17.4)	<b>0.009<sup>e</sup></b>	4 (3.1)	1 (1.3)	3 (6.0)	0.298 <sup>e</sup>	0.767 <sup>e</sup>
<b><i>Dientamoeba</i></b>	2 (0.6)	1 (0.4)	1 (1.0)	0.502 <sup>e</sup>	0 (0.0)	0 (0.0)	0 (0.0)	-	2 (1.6)	1 (1.3)	1 (2.0)	>0.99 <sup>e</sup>	0.166 <sup>e</sup>
<b>&gt;1 parasite detected</b>	19 (5.5)	13 (5.4)	6 (5.9)	0.827	24 (12.8)	22 (13.4)	2 (8.7)	0.744 <sup>e</sup>	10 (7.8)	6 (7.6)	4 (8.0)	>0.99 <sup>e</sup>	0.152
<b>Mixed infections</b>	40 (11.6)	34 (14.0)	6 (5.9)	<b>0.034</b>		23 (14.0)	2 (8.7)	0.744 <sup>e</sup>	14 (10.9)	10 (12.7)	4 (8.0)	0.564 <sup>e</sup>	0.504
<b>Virus-bacteria</b>					25 (13.4)								
<b>Virus-parasite</b>	35 (10.2)	29 (11.9)	6 (5.9)	0.094	25 (13.4)	23 (14.0)	2 (8.7)	0.744 <sup>e</sup>	11 (8.5)	7 (8.9)	4 (8.0)	>0.99 <sup>e</sup>	0.183
<b>Bacteria-parasite</b>	72 (20.9)	60 (24.7)	12 (11.9)	<b>0.008</b>	46 (24.6)	41 (25.0)	5 (21.7)	0.734	23 (17.8)	16 (20.3)	7 (14.0)	0.366	0.152
<b>&gt;1 pathogen detected</b>	115 (33.4)	92 (37.9)	23 (22.8)	<b>0.007</b>	73 (39.0)	66 (40.2)	7 (30.4)	0.366	40 (31.0)	26 (32.9)	14 (28.0)	0.557	0.143

261 <sup>a</sup>Total is 344 for overall analysis and 316 for the HIV analysis due to 28 controls with unknown HIV-status being excluded from the HIV analysis; <sup>b</sup>*p*-value comparing  
262 pathogen detection in cases versus controls (for HIV-infected and HIV-uninfected groups respectively); <sup>c</sup>*p*-value comparing pathogen detection in HIV-infected versus HIV-  
263 uninfected persons (cases and controls combined); <sup>d</sup> The following parasites were screened for but not detected: *Vibrio cholerae*, *Yersinia enterocolitica*, *E. histolytica*,  
264 *Strongyloides* spp., *Cyclospora*, *Hymenolepsis*, *Ascaris*, *Taenia*, *Trichuris*, *Ancylostoma*, *Enterobius*, *Necator*: <sup>e</sup> Fisher's exact test

265 *Effect of CD4+ cell count and treatment on clinical presentation and pathogen detection amongst*  
266 *HIV-infected diarrhoeal cases*

267 For HIV-infected cases, presentation did not differ by CD4+ cell count for duration of symptoms,  
268 fever, vomiting, fatigue, nausea, respiratory symptoms, abdominal pain, dermatological symptoms,  
269 chills, headache, dysentery, arthralgia, myalgia, neurological symptoms or painful lymphadenopathy  
270 (Table S2). There was an increased proportion of cases reporting weight loss with lower CD4+ cell  
271 counts (91.4%, 81.0% and 62.5% for CD4+ cell counts of <200, 200-500, >500 cells/mm<sup>3</sup> respectively;  
272  $p=0.032$ ). Pathogens were detected more frequently in cases with low CD4+ cell counts (75.7%,  
273 42.9% and 37.5% for CD4+ cell counts of <200, 200-500, >500 cells/mm<sup>3</sup> respectively;  $p=0.004$ )  
274 (Table S3). *Cryptosporidium* spp. specifically, was detected more often in those with low CD4+ cell  
275 counts (25.7%, 4.8% and 0.0% for CD4+ cell counts of <200, 200-500, >500 cells/mm<sup>3</sup> respectively;  
276  $p=0.039$ ).

277 Clinical presentation was similar amongst HIV-infected cases on ART and those not on ART (Table  
278 S4). Those on cotrimoxazole prophylaxis were more likely to experience fatigue (88.9% versus 69.3%,  
279  $p=0.005$ ), weight loss (90.5% versus 76.1%,  $p=0.023$ ) and chills (50.8% versus 15.9%,  $p<0.001$ ) than  
280 those not on cotrimoxazole. Pathogen detection was similar amongst HIV-infected cases on ART and  
281 those not on ART (72.3% versus 88.5%,  $p=0.082$ ) (Table S5). Parasites, specifically *Cystoisospora* spp.  
282 were more commonly detected amongst patients on cotrimoxazole compared with those not on  
283 cotrimoxazole (27.0% versus 11.4%,  $p=0.014$ ). Other pathogens were found in similar proportions  
284 across treatment groups.

285 *Clostridioides difficile* detection

286 *C. difficile* was detected in 14 cases, 13 of which were in HIV-infected patients (92.9%). Symptoms  
287 were similar between cases in which *C. difficile* was detected and those without *C. difficile* detection,  
288 however those with *C. difficile* detected were more likely to have had a longer duration of illness  
289 before admission (6.5 (IQR 4-11) days versus 4 (IQR 2-7) days) (data not shown). It is important to

290 distinguish *C. difficile* colonisation from disease to avoid unnecessary antimicrobial therapy. The case  
291 definition, as per the guidelines for diagnostic and clinical management of *C. difficile* from the South  
292 African Society for Clinical Microbiology, includes onset of diarrhoea more than 48 hours after  
293 admission, or diarrhoea that continues for 3 days post admission and where there is no likely  
294 alternatively cause (no other pathogens detected or use of laxatives), or where the patient has had  
295 an admission or antibiotics use in the past 12 weeks.<sup>40</sup> Three of the 14 cases did not match this case  
296 definition as they did not have an admission in the past 12 weeks and had multiple pathogens  
297 detected on PCR. These three cases were however HIV-infected. Five of the cases had no other  
298 pathogens detected on PCR, all of which were HIV-infected. Eight of the cases did have a prior  
299 admission, however the majority of these (n=6, 75.0%) had multiple pathogens detected on PCR. In  
300 addition, the guidelines recommend that specimens testing positive for *C. difficile* on PCR (which is  
301 highly sensitive for detection of *C. difficile*), should have further toxins A/B immunoassays performed  
302 (which have high specificity for diagnosis of *C. difficile* infection). This was not done in the current  
303 analysis.

#### 304 Discussion

305 Despite advances in HIV treatment, diarrhoea amongst HIV-infected patients remains a significant  
306 public health challenge<sup>19</sup>. Our study found that the majority (67.5%) of patients 5 years and older  
307 with known HIV-status admitted to the study sites with diarrhoea were HIV-infected, highlighting the  
308 importance of HIV-related illnesses among South African adults hospitalised with diarrhoea. The  
309 Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 treatment target aims to ensure  
310 that 90% of the HIV-infected population are diagnosed, 90% of those diagnosed are initiated on ART  
311 and 90% of those on ART should achieve viral suppression<sup>41</sup>. A recent South African analysis  
312 estimated that 70.7% of diagnosed HIV-infected individuals have initiated ART, and 87.4% of these  
313 are thought to be virally suppressed<sup>41</sup>. Proportions reported in the current analysis reflect these  
314 numbers, as 83.3% of HIV-infected patients with known ART status were on treatment, however a



315 large proportion of HIV-infected patients included in this analysis had CD4+ cell count <200 cells/ $\mu$ l  
316 (70/99, 70.7%) indicating that they are unlikely to be virally suppressed. Mpumalanga (home  
317 province to the majority of the patients included in this analysis) is the only South African province in  
318 which the third-90 indicator value (the percentage of those on ART that are virally suppressed) is  
319 below 85%<sup>41</sup>. It is also likely that the study design was skewed towards detection of poorly  
320 suppressed HIV cases as they are most likely to be hospitalised for diarrhoea. Diarrhoea in patients  
321 with viral suppression will likely be seen at a clinic level. Further studies at clinic level are  
322 recommended in order to include a broader spectrum of cases. The clinical presentation of  
323 diarrhoea in HIV-infected cases differs to that of HIV-uninfected cases. HIV-infected diarrhoeal cases  
324 were more likely to have symptoms for a longer duration before admission and to suffer from  
325 weight loss and nausea. HIV-uninfected cases were more likely to suffer from dysentery. This finding  
326 has not been reported in other studies, however it is likely related to aetiological differences  
327 between HIV-infected and HIV-uninfected diarrhoeal patients. Amongst HIV-infected cases, patients  
328 on cotrimoxazole were more likely to experience fatigue, weight loss and chills and were more likely  
329 to have parasites detected, specifically *Cystoisospora* spp., compared to those not on cotrimoxazole.  
330 This is an interesting finding since cotrimoxazole is the prescribed treatment for this pathogen. Since  
331 all patients with CD4+ <200 cells/ $\mu$ l should receive cotrimoxazole prophylaxis, it can be used as a  
332 surrogate marker for advanced HIV disease. However this finding may also point to changes in  
333 *Cystoisospora* sensitivity for cotrimoxazole or may indicate that these patients are carriers or take  
334 longer to clear the pathogen. The possibility of drug resistance should be further investigated in  
335 future studies.

336 The use of molecular methods and the expanded panel of pathogens included in testing resulted in a  
337 high pathogen detection rate, with pathogen detection being significantly higher in cases compared  
338 with controls. Although viruses were commonly detected (18.5% of all specimens tested) and were  
339 more likely to be detected in cases as compared with controls, when stratified by HIV status, viruses  
340 were not significantly associated with diarrhoea in this study. Although this lack of association may

341 be partly due to asymptomatic carriage of viruses (specifically in HIV-uninfected patients), it is likely  
342 that the sample size was insufficient to determine significant differences between cases and controls  
343 when stratified by HIV status. Interestingly, norovirus GII was more prevalent in HIV-infected  
344 individuals than HIV-uninfected individuals and detection in HIV-infected individuals was limited to  
345 cases. Previous findings from South Africa have shown that HIV-infected children are more likely to  
346 suffer poor outcomes related to norovirus infection<sup>42</sup>, however detection rates were similar amongst  
347 HIV-infected and –uninfected children. This increased detection of norovirus in HIV-infected patients  
348  $\geq 5$  years of age has not been previously described. Bacteria was detected in 43.9% of specimens  
349 tested and was significantly associated with diarrhoea overall and amongst HIV-uninfected patients.  
350 Interestingly, prevalence of bacterial pathogens was high in both cases and controls within the HIV-  
351 infected group. This was specifically due to the high prevalence of *E. coli* spp. (including ETEC, EPEC  
352 and EAEC) amongst HIV-infected controls. High *E. coli* spp. colonisation rates in HIV-infected  
353 patients have been documented in other settings<sup>43</sup>. We found *Shigella* spp, *Salmonella* spp. and *H.*  
354 *pylori* to be significantly associated with diarrhoea in the current study, specifically amongst HIV-  
355 uninfected patients. It's likely that the sample size was insufficient to detect a difference in  
356 prevalence between cases and controls in the HIV-uninfected group. *Campylobacter* spp. and *C.*  
357 *difficile* were detected more often in HIV-infected patients as compared with HIV-uninfected  
358 patients but were not significantly associated with diarrhoea (likely due to small sample sizes).  
359 As expected from literature<sup>14</sup>, parasite prevalence was significantly higher amongst HIV-infected  
360 compared with HIV-uninfected patients, specifically *Cystoisospora*, *Cryptosporidium* spp. and  
361 *Enterocytozoon* spp., although only *Cystoisospora* was significantly associated with diarrhoea  
362 amongst HIV-infected patients. The case-control analysis indicated that *Blastocystis* and *Schistosoma*  
363 are unlikely to be causative agents of diarrhoea since these pathogens were detected at higher rates  
364 in controls than in cases. Prevalence of *Schistosoma* among healthy individuals has been reported to  
365 be as high as 51.2% in the Democratic Republic of Congo and is likely to be higher in villages and  
366 rural areas where water is collected from rivers and dam<sup>44</sup>. *Blastocystis* has been noted as an

367 important cause of diarrhoea amongst immunosuppressed patients<sup>45</sup>, however this was not found in  
368 the current study.

369 Diarrhoeal aetiology differed with HIV status, with *Shigella* spp. and *Salmonella* spp. being prevalent  
370 amongst HIV-uninfected cases and *Shigella* spp., *Cystoisospora*, and *Cryptosporidium* spp. being  
371 prevalent amongst HIV-infected cases. These differences should be considered during development  
372 of diagnostic and treatment guidelines. This study highlights the importance of *Shigella* spp. in  
373 diarrhoeal morbidity amongst adults (regardless of HIV status). According to the Global Burden of  
374 Disease Study (GBD), *Shigella* spp. were the leading cause of diarrhoeal deaths amongst individuals  
375 over the age of 5 years and the second leading cause of death in young children in 2016<sup>1</sup>. While  
376 there is currently no approved *Shigella* vaccine, there are several candidates which show promise for  
377 efficacy testing<sup>46</sup>. In order to introduce a candidate vaccine, burden estimates are required.

378 Although a larger sample size is required, this analysis gives an indication of the high burden of  
379 *Shigella* spp. in our setting. Further work is required to determine if HIV-infected individuals should  
380 be considered as a risk group for possible target should *Shigella* vaccine become available.

381 Our results are in line with clinical literature which indicates a shift in diarrhoeal aetiology with CD4+  
382 cell count amongst HIV-infected patients. Pathogen detection was high in those with CD4+ cell  
383 counts <200 cells/ $\mu$ l, indicating increased opportunistic infections (specifically *Cryptosporidium* spp.).  
384 Pathogens could only be detected in just over a third of cases with high CD4+ cell count (>500  
385 cells/ $\mu$ l), suggesting that these cases are possibly drug-related. This finding may be useful for  
386 treatment guidelines. It also highlights the importance of addressing diarrhoea in patients on ART  
387 especially since chronic diarrhoea has been identified as a major cause of dropout from ART care  
388 services<sup>47</sup>.

389 Detection of *C. difficile* in this study was almost exclusive to HIV-infected participants (13/14, 92.9%;  
390 including 12 cases and 1 control). Data from another hospital study in Gauteng Province estimated  
391 that community acquired *C. difficile* infections represent only 1.3% of cases (with the remaining

392 98.7% being hospital acquired)<sup>48</sup>. Our study design excluded cases of hospital-acquired diarrhoea, as  
393 enrolment and specimen collection was done within 48 hours of admission. The 5.4% *C. difficile*  
394 prevalence reported here is lower than systematic review estimates of 15.8% amongst symptomatic  
395 non-immunosuppressed in-patients from LMIC<sup>49</sup>. This systematic review indicated similar rates  
396 amongst immunosuppressed and non-immunosuppressed populations<sup>49</sup> whereas the current study  
397 found that *C. difficile* was more commonly detected in HIV-infected cases than in –uninfected cases.  
398 While not considered an opportunistic infection, *C. difficile* is associated with exposure to healthcare  
399 settings and with the use of antibiotics, both of which are increased amongst HIV-patients<sup>50</sup>. The  
400 increased management of HIV patients in an outpatient setting<sup>51</sup> may dispute the inclusion of recent  
401 admission as a criterion in the case definition. There is also growing evidence to suggest the  
402 possibility of *C. difficile* being an important community-acquired pathogen<sup>51</sup>, and consideration of  
403 this should be given in populations with high HIV prevalence.

404 A major limitation of this study was the small sample size which restricted the analysis (attributable  
405 fractions and odds ratios could not be calculated as many categories had zero count). The ANDEMIA  
406 study was not specifically aimed at enrolling HIV-infected cases and controls, therefore this analysis  
407 relied on incidental HIV enrolments. Enrolment, specifically of controls, was also hampered by  
408 COVID-19 restrictions. An extension of this analysis would benefit from enrolling controls from HIV  
409 clinics. Viral load was not analysed here, since few recent results were available; thus recent CD4+  
410 cell count was used as a proxy. CD4+ cell counts were not available for all HIV-infected cases at the  
411 time of admission. Many of those without CD4+ cell counts available were matched from NHLS data,  
412 however these tests were not always performed at the same time as the enrolment. We used a cut  
413 off of 12 months on either side of enrolment for CD4+ cell counts as this was deemed to be a  
414 reasonable estimation of the CD4+ cell count at admission. In cases where there were significant  
415 changes in CD4+ cell counts over time, these may have been incorrectly quantified. There were also  
416 limited data available for antibiotic use. Date of last dose was available, however start date for  
417 antibiotic course was not collected. This has limitations specifically for the *C. difficile* analysis, since

418 we could not determine the length of antibiotic courses. Future studies should also investigate the  
419 expansion of diagnostic testing for *M. avium* which was not done in the present study.

420 In conclusion, this study highlights the importance of HIV-related diarrhoea amongst South African  
421 inpatients  $\geq 5$  years of age, and underscores the importance of research in a high HIV prevalence  
422 setting in order to improve the understanding of aetiology of diarrhoea. These data are important  
423 for development of guidelines and treatment protocols as well as for preventative interventions,  
424 such as vaccine introduction. Our data specifically highlights the importance of *Shigella* spp. amongst  
425 both HIV-infected and HIV-uninfected diarrhoeal patients. We suggest that research be expanded to  
426 primary healthcare levels in order to include a broader spectrum of HIV disease, specifically to  
427 investigate diarrhoea in individuals with well-controlled HIV.

#### 428 Acknowledgments

429 We wish to acknowledge the ANDEMIA participants, funders, staff and clinical staff at the hospitals.

430 Thank you to Ann Christin Vietor for statistical assistance.

431

432

433

434

435

436

437

438

439

440 References:

- 441 1. Troeger C, Blacker BF, Khalil IA, Rao PC, Cao S, Zimsen SR, et al. Estimates of the global,  
442 regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a  
443 systematic analysis for the Global Burden of Disease Study 2016. *Lancet Infect Dis.*  
444 2018;18(11):1211–28.
- 445 2. Fischer Walker CL, Black RE. Diarrhoea morbidity and mortality in older children, adolescents,  
446 and adults. *Epidemiol Infect.* 2010;138:1215–26.
- 447 3. Farthing M, Salam MA, Lindberg G, Dite P, Khalif I, Salazar-Lindo E, et al. Acute diarrhea in  
448 adults and children: A global perspective. *J Clin Gastroenterol.* 2013;47(1):12–20.
- 449 4. Dwivedi K, Prasad G, Saini S, Mahajan S, Lal S, Baveja U. Enteric opportunistic parasites  
450 among HIV infected individuals: associated risk factors and immune status. *Jpn J Infect Dis.*  
451 2007;60:76–81.
- 452 5. Kelly P, Todd J, Sianongo S, Mwansa J, Sinsungwe H, Katubulushi M, et al. Susceptibility to  
453 intestinal infection and diarrhoea in Zambian adults in relation to HIV status and CD4 count.  
454 *BMC Gastroenterol.* 2009;9(7).
- 455 6. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H. A comparative risk  
456 assessment of burden of disease and injury attributable to 67 risk factor clusters in 21  
457 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.  
458 *Lancet.* 2012;380(9859).
- 459 7. Grace D. Food safety in low and middle income countries. *Int J Environ Res Public Heal.*  
460 2015;12:10490–507.
- 461 8. Jansen A, Stark K, Kunkel J, Schreier E, Ignatius R, Liesenfeld O, et al. Aetiology of community-  
462 acquired, acute gastroenteritis in hospitalised adults: a prospective cohort study. *BMC Infect*  
463 *Dis.* 2008;8(1):1–7.

- 464 9. Bresee JS, Marcus R, Venezia RA, Keene WE, Morse D, Thanassi M, et al. The etiology of  
465 severe acute gastroenteritis among adults visiting emergency departments in the United  
466 States. *J Infect Dis.* 2012;205(9):1374–81.
- 467 10. Fletcher S, Stark D, Ellis J. Prevalence of gastrointestinal pathogens in Sub-Saharan Africa:  
468 systematic review and meta-analysis. *J Public Heal Africa.* 2011;2(2).
- 469 11. Joint United Nations Programme on HIV/AIDS (UNAIDS). The Gap Report [Internet]. 2014.  
470 Available from: [https://unaidstest.unaids.org/sites/default/files/unaidstest.unaids.org/sites/default/files/unaidspublication/2014/](https://unaidstest.unaids.org/sites/default/files/unaidstest.unaids.org/sites/default/files/unaidstest.unaids.org/sites/default/files/unaidstest.unaids.org/sites/default/files/unaidspublication/2014/UNAIDS_Gap_report_en.pdf)  
471 [UNAIDS\\_Gap\\_report\\_en.pdf](https://unaidstest.unaids.org/sites/default/files/unaidstest.unaids.org/sites/default/files/unaidspublication/2014/UNAIDS_Gap_report_en.pdf)  
472
- 473 12. Germani Y, Minssart P, Vohito M, Yassibanda S, Glaziou P, Hocquet D, et al. Etiologies of  
474 acute, persistent, and dysenteric diarrheas in adults in Bangui, Central African Republic, in  
475 relation to human immunodeficiency virus serostatus. *Am J Trop Med Hyg.* 2017;59(6):1008–  
476 14.
- 477 13. Acácio S, Nhampossa T, Quintó L, Vubil D, Saco C, Kotloff K, et al. The role of HIV infection  
478 in the etiology and epidemiology of diarrheal disease among children aged 0–59 months in  
479 Manhiça District, Rural Mozambique. *Int J Infect Dis.* 2018;73:10–7.
- 480 14. Feasey NA, Healey P, Gordon MA. Review article: the aetiology, investigation and  
481 management of diarrhoea in the HIV-positive patient. *Aliment Pharmacol Ther.* 2011;34:587–  
482 603.
- 483 15. Thomas P, Pollok R, Gazzard B. Enteric viral infections as a cause of diarrhoea in the acquired  
484 immunodeficiency syndrome. *HIV Med.* 1999;1:19–24.
- 485 16. Wang Z, Liu Q, Liu H, Li S, Zhang L, Zhao Y, et al. Prevalence of *Cryptosporidium*, microsporidia  
486 and *Isospora* infection in HIV-infected people: a global systematic review and meta-analysis.  
487 *Parasites and Vectors.* 2018;11(28).

- 488 17. Vyas N, Pathan N, Aziz A. Enteric pathogens in HIV-positive patients with diarrhoea and their  
489 correlation with CD4+ T-lymphocyte counts. *Trop Parasitol.* 2012;2(1):29–34.
- 490 18. Asmuth D, Clay P, Blick G, Chaturvedi P, MacFarlane K. Incidence and prevalence of diarrhoea  
491 in HIV clinical trials in the recent post-cART era: analysis of data from 38 clinical trials from  
492 2008-2017 over 21,000 patients. In: 22nd International AIDS Conference. Amsterdam; 2018.
- 493 19. Logan C, Beadsworth M, Beeching N. HIV and diarrhoea: what is new? *Curr Opin Infect Dis.*  
494 2016;29(5):486–94.
- 495 20. Harris E, Washington K. Manifestations of immunodeficiency in the GI tract. In: Odze R,  
496 Goldblum J, editors. *Surgical pathology of the GI tract, liver, biliary tract, and pancreas*  
497 (Second edition). 2nd ed. Elsevier Inc.; 2009. p. 81–96.
- 498 21. Awole M, Gebre-Selassie G, Kassa T, Kibru G. Isolation of potential bacterial pathogens from  
499 the stool of HIV-infected and HIV-non-infected patients and their antimicrobial susceptibility  
500 patterns in Jimma Hospital, South West Ethiopia. *Ethiop Med J.* 2002;40:353–64.
- 501 22. Dikman AE, Schonfeld E, Srisarajivakul NC, Poles MA. Human Immunodeficiency Virus-  
502 Associated Diarrhea: Still an Issue in the Era of Antiretroviral Therapy. *Dig Dis Sci.*  
503 2015;60(8):2236–45.
- 504 23. Oude Munnink B, Canuti M, Deijs M, de Vries M, Jebbink M, Rebers S, et al. Unexplained  
505 diarrhoea in HIV-1 infected individuals. *BMC Infect Dis.* 2014;14(22).
- 506 24. Call S, Heudebert G, Saag M, Wilcox C. The changing etiology of chronic diarrhea in HIV-  
507 infected patients with CD4 cell counts less than 200 cells/mm<sup>3</sup>. *Am J Gastroenterol.*  
508 2000;95(11):3142–6.
- 509 25. Rubaihayo J, Tumwesigye N, Konde-Lule J, Wamani H, Nakku-Joloba E, Makumbi F. Frequency  
510 and distribution patterns of opportunistic infections associated with HIV/AIDS in Uganda.  
511 *BMC Res Notes.* 2016;9(1).



- 512 26. Rowe J, Shah S, Motlhagodi S, Bafana M, Tawanana E, Truong H, et al. An epidemiologic  
513 review of enteropathogens in Gaborone, Botswana: Shifting patterns of resistance in an HIV  
514 epidemic region. *PLoS One*. 2010;5(6):e10924.
- 515 27. Ahmadpour E, Safarpour H, Xiao L, Zarean M, K H-N, Barac A, et al. Cryptosporidiosis in HIV-  
516 positive patients and related risk factors: A systematic review and meta-analysis. *Parasite*.  
517 2020;27(27).
- 518 28. Obi CL, Bessong PO. Diarrhoeagenic bacterial pathogens in HIV-positive patients with  
519 diarrhoea in rural communities of Limpopo Province, South Africa. *J Heal Popul Nutr*.  
520 2002;20(3):230–4.
- 521 29. Groome MJ, Madhi SA. Five-year cohort study on the burden of hospitalisation for acute  
522 diarrhoeal disease in African HIV-infected and HIV-uninfected children: Potential benefits of  
523 rotavirus vaccine. *Vaccine*. 2012;30(S1):A173–8.
- 524 30. Cheung T, Teich S. Cytomegalovirus infection in patients with HIV infection. *Mt Sinai J Med*.  
525 1999;66(2):113–24.
- 526 31. Azer S, Limaiem G. Cytomegalovirus colitis. Florida: StatPearls; 2022. 6 p.
- 527 32. Legenza L, Barnett S, Rose W, Bianchini M, Safdar N, Coetzee R. Epidemiology and outcomes  
528 of *Clostridium difficile* infection among hospitalised patients: results of a multicentre  
529 retrospective study in South Africa. *BMJ Glob Heal*. 2018;3(4):e000889.
- 530 33. Johnson L, Dorrington R, Moolla H. Progress towards the 2020 targets for HIV diagnosis and  
531 antiretroviral treatment in South Africa. *South Afr J HIV Med*. 2017;18(1):a694.
- 532 34. Moshabela M, Macpherson P, Ezard N, Freat E, Mashimbye L, Elliott J, et al. Clinical and  
533 social determinants of diarrhoeal disease in a rural HIV/AIDS clinic , South Africa : a case-  
534 control study. *Int J STD AIDS*. 2014;23(5):346–50.

- 535 35. Elfstrand L, Floren C. Management of chronic diarrhea in HIV-infected patients: current  
536 treatment options, challenges and future directions. *HIV AIDS*. 2010;2:219–24.
- 537 36. Riddle MS, Dupont HL, Connor BA. ACG clinical guideline: Diagnosis, treatment, and  
538 prevention of acute diarrheal infections in adults. *Am J Gastroenterol*. 2016;111(5):602–22.
- 539 37. Schubert G, Achi V, Ahuka S, Belarbi E, Bourhaima O, Eckmanns T, et al. The African Network  
540 for Improved Diagnostics, Epidemiology and Management of common infectious Agents.  
541 *BMC Infect Dis*. 2021;21(1):539.
- 542 38. Delpont S, Swanepoel J, Odendaal P, Roux P. Incidence of retinopathy of prematurity in very-  
543 low-birth-weight infants born at Kalafong Hospital, Pretoria. *South African Med J*.  
544 2002;92(12):986–90.
- 545 39. Msimang VMY, Page N, Groome MJ, Moyes J, Cortese MM, Seheri M, et al. Impact of  
546 rotavirus vaccine on childhood diarrheal hospitalization after introduction into the South  
547 African Public Immunization Program. *Pediatr Infect Dis J*. 2013;32(12):1359–64.
- 548 40. Nana T, Moore C, Boyles T, Brink AJ, Cleghorn J, Devenish LM, et al. South African Society of  
549 Clinical Microbiology *Clostridioides difficile* infection diagnosis, management and infection  
550 prevention and control guideline. *South African J Infect Dis*. 2020;35(1).
- 551 41. Marinda E, Simbayi L, Zuma K, Zungu N, Moyo S, Kondlo L, et al. Towards achieving the 90–  
552 90–90 HIV targets: Results from the South African 2017 national HIV survey. *BMC Public*  
553 *Health*. 2020;20(1):1–12.
- 554 42. Page NA, Groome MJ, Nadan S, Netshikweta R. Norovirus epidemiology in South African  
555 children <5 years hospitalised for diarrhoeal illness between 2009 and 2013. *Epidemiol Infect*.  
556 2017;
- 557 43. Garcia C, Chinchu O, Leon M, Iglesias D, Barletta F, Mercado E, et al. Short Report : High  
558 Frequency of Diarrheagenic *Escherichia coli* in Human Immunodeficiency Virus (HIV) Patients

- 559 with and without Diarrhea in Lima , Perú. *Am J Trop Med Hyg.* 2010;82(6):1118–20.
- 560 44. Madinga J, Id LM, Barbe B, Linsuke S, Hermy M, Heroes A, et al. Non-typhoidal Salmonella  
561 intestinal carriage in a Schistosoma mansoni endemic community in a rural area of the  
562 Democratic Republic of Congo. *PLoS Negl Trop Dis.* 2020;14(10):e0007875.
- 563 45. Rao K, Sekar U, Iraivan KT, Abraham G, Soundararajan P. Blastocystis hominis — An Emerging  
564 Cause of Diarrhoea in Renal Transplant Recipients. *J Assoc Physicians India.* 2003;51:719–21.
- 565 46. Hosangadi D, Smith PG, Giersing BK. Considerations for using ETEC and Shigella disease  
566 burden estimates to guide vaccine development strategy. *Vaccine.* 2019;37(50):7372–80.
- 567 47. Asimwe SB, Kanyesigye M, Bwana B, Okello S, Muyindike W. Predictors of dropout from care  
568 among HIV-infected patients initiating antiretroviral therapy at a public sector HIV treatment  
569 clinic in sub-Saharan Africa. *BMC Infect Dis.* 2016;16(43).
- 570 48. Godinho L, Feldman C. Clostridium difficile infection in Johannesburg, South Africa. *Hosp  
571 Pract.* 2018;46(5):287–94.
- 572 49. Forrester JD, Cai LZ, Mbanje C, Rinderknecht TN, Wren SM. Clostridium difficile infection in  
573 low- and middle-human development index countries: a systematic review. *Trop Med Int  
574 Heal.* 2017;22(10):1223–32.
- 575 50. Revolinski SL, Munoz-Price LS. Clostridium difficile in Immunocompromised Hosts: A Review  
576 of Epidemiology, Risk Factors, Treatment, and Prevention. *Clin Infect Dis.* 2019;68(12):2144–  
577 53.
- 578 51. Collini PJ, Kuijper E, Dockrell DH. Clostridium Difficile Infection in Patients with HIV/AIDS. *Curr  
579 HIV/AIDS Rep.* 2013;10:273–82.
- 580
- 581

582 Supplementary tables:

583 Table S1: Pathogens included in molecular testing

Pathogen	Testing platform
<b>Viruses</b>	
Norovirus GI	FTD viral gastroenteritis, TaqMan Array Cards
Norovirus GII	FTD viral gastroenteritis, TaqMan Array Cards
Human astrovirus	FTD viral gastroenteritis, TaqMan Array Cards
Rotavirus	FTD viral gastroenteritis, TaqMan Array Cards
Human adenovirus	FTD viral gastroenteritis, TaqMan Array Cards
Sapovirus	FTD viral gastroenteritis, TaqMan Array Cards
Enterovirus	TaqMan Array Cards
CMV	Monoplex PCR
<b>Bacteria</b>	
<i>Campylobacter coli/jejuni/lari</i>	FTD bacterial gastroenteritis, TaqMan Array Cards
<i>Clostridioides difficile</i>	FTD bacterial gastroenteritis, TaqMan Array Cards
<i>Escherichia coli</i> verotoxin positives	FTD bacterial gastroenteritis
<i>Salmonella</i> spp.	FTD bacterial gastroenteritis, TaqMan Array Cards
<i>Shigella</i> spp.	FTD bacterial gastroenteritis, TaqMan Array Cards
Enteroinvasive <i>Escherichia coli</i>	FTD bacterial gastroenteritis, TaqMan Array Cards
<i>Yersinia enterocolitica</i>	FTD bacterial gastroenteritis, TaqMan Array Cards
EAEC	TaqMan Array Cards
EPEC	TaqMan Array Cards
ETEC	TaqMan Array Cards
STEC/VTEC	FTD bacterial gastroenteritis; TaqMan Array Cards
<i>E. coli</i> O157	TaqMan Array Cards
<b>Parasites</b>	
<i>Plesiomonas shigelloides</i>	TaqMan Array Cards
<i>Entamoeba histolytica</i>	FTD enteric parasites, TaqMan Array Cards, SeeGene Allplex
<i>Cryptosporidium</i> spp.	FTD enteric parasites, TaqMan Array Cards, SeeGene Allplex
<i>Giardia lamblia</i>	FTD enteric parasites, TaqMan Array Cards, SeeGene Allplex
<i>Vibrio cholerae</i>	TaqMan Array Cards
<i>Helicobacter pylori</i>	TaqMan Array Cards
<i>Schistosoma</i>	TaqMan Array Cards
<i>Enterocytozoon</i> spp.	TaqMan Array Cards, SeeGene Allplex
<i>Strongyloides stercoralis</i>	TaqMan Array Cards, SeeGene Allplex
<i>Cytoisospora belli</i>	TaqMan Array Cards
<i>Blastocystis hominis</i>	SeeGene Allplex
<i>Dientamoeba fragilis</i>	SeeGene Allplex
<i>Cyclospora cayentanensis</i>	SeeGene Allplex
<i>Hymenolepis nana</i>	SeeGene Allplex

<i>Ascaris lumbricoides</i>	SeeGene Allplex
<i>Taenia</i> spp.	SeeGene Allplex
<i>Trichuris trichiura</i>	SeeGene Allplex
<i>Ancylostoma duodenale</i>	SeeGene Allplex
<i>Enterobius vermicularis</i>	SeeGene Allplex
<i>Necator americanus</i>	SeeGene Allplex

584

585 Table S2: Clinical presentation for HIV-infected cases, stratified by CD4+ cell counts

	CD4+ cell count <sup>a</sup>			p-value
	<200 cells/ $\mu$ l (n=70)	200-500 cells/ $\mu$ l (n=21)	>500 cells/ $\mu$ l (n=8)	
<b>Duration of symptoms before admission – median (IQR)</b>	6 (3-10)	7 (3.5-12)	5.5 (3-7)	0.822
<b>Chronic/persistent diarrhoea</b>	6 (8.6%)	2 (9.5%)	1 (12.5%)	0.855
<b>Weight loss</b>	64 (91.4%)	17 (81.0%)	5 (62.5%)	<b>0.032</b>
<b>Fatigue</b>	58 (82.9%)	16 (76.2%)	5 (62.5%)	0.293
<b>Nausea</b>	6 (75.0%)	15 (71.4%)	6 (75.0%)	>0.99
<b>Vomiting</b>	48 (68.6%)	14 (66.7%)	6 (75.0%)	>0.99
<b>Fever (current or history)</b>	46 (65.7%)	14 (66.7%)	5 (62.5%)	>0.99
<b>Abdominal pain</b>	41 (58.6%)	14 (66.7%)	4 (50.0%)	0.667
<b>Respiratory symptoms</b>	33 (47.1%)	12 (57.1%)	1 (12.5%)	0.097
<b>Chills</b>	32 (45.7%)	7 (33.3%)	3 (37.5%)	0.634
<b>Headache</b>	32 (45.7%)	7 (33.3%)	4 (50.0%)	0.635
<b>Dermatological symptoms</b>	13 (18.6%)	3 (14.3%)	0 (0.0%)	0.494
<b>Arthralgia</b>	11 (15.7%)	6 (28.6%)	0 (0.0%)	0.171
<b>Myalgia</b>	11 (15.7%)	1 (4.8)%	0 (0.0%)	0.334
<b>Neurological symptoms</b>	5 (7.1%)	0 (0.0%)	1 (12.5%)	0.347
<b>Dysentery <sup>b</sup></b>	2 (2.9%)	0 (0.0%)	0 (0.0%)	>0.99
<b>Painful swollen glands</b>	2 (2.9%)	0 (0.0%)	0 (0.0%)	>0.99

586 <sup>a</sup> CD4+ count within 12 months of enrolment only known for 99 of the 164 HIV-infected patients included in  
587 molecular testing; <sup>b</sup> Dysentery defined as self-reported blood in the stool.

588

589

590

591

592

593

594

595 Table S3: Pathogen detection in specimens of HIV-infected cases, stratified by CD4+ cell count

	CD4+ count <sup>a</sup> - n (%)			p-value
	>500 cells/ $\mu$ l (n=8)	200-500 cells/ $\mu$ l (n=21)	<200 cells/ $\mu$ l (n=70)	
<b>Any pathogen</b>	5 (62.5)	12 (57.1)	59 (84.3)	<b>0.022</b>
<b>Virus</b>	2 (25.0)	5 (23.8)	19 (27.1)	>0.99
<b>Adenovirus</b>	0 (0.0)	5 (23.8)	8 (11.4)	0.170
<b>Adenovirus 40/41</b>	0 (0.0)	1 (4.8)	0 (0.0)	0.293
<b>Norovirus</b>	0 (0.0)	1 (4.8)	6 (8.6)	>0.99
<b>Norovirus GI</b>	0 (0.0)	0 (0.0)	0 (0.0)	-
<b>Norovirus GII</b>	0 (0.0)	1 (4.8)	6 (8.6)	>0.99
<b>Enterovirus</b>	2 (25.0)	0 (0.0)	7 (10.0)	0.068
<b>CMV</b>	0 (0.0)	0 (0.0)	2 (2.9)	>0.99
<b>Astrovirus</b>	0 (0.0)	0 (0.0)	2 (2.9)	>0.99
<b>Rotavirus</b>	0 (0.0)	0 (0.0)	1 (1.4)	>0.99
<b>Sapovirus</b>	0 (0.0)	0 (0.0)	1 (1.4)	>0.99
<b>&gt;1 virus detected</b>	0 (0.0)	1 (4.8)	5 (7.1)	>0.99
<b>Bacteria</b>	4 (50.0)	8 (38.1)	35 (50.0)	0.638
<b>Shigella spp.</b>	1 (12.5)	1 (4.8)	12 (17.1)	0.389
<b>Salmonella spp.</b>	0 (0.0)	0 (0.0)	7 (10.0)	0.322
<b>C. difficile</b>	0 (0.0)	1 (4.8)	9 (12.9)	0.450
<b>Campylobacter</b>	0 (0.0)	0 (0.0)	4 (5.7)	0.695
<b>STEC</b>	0 (0.0)	0 (0.0)	0 (0.0)	-
<b>ETEC</b>	0 (0.0)	0 (0.0)	2 (2.9)	>0.99
<b>EPEC</b>	0 (0.0)	0 (0.0)	6 (8.6)	0.464
<b>EAEC</b>	1 (12.5)	4 (19.1)	8 (11.4)	0.622
<b>O157</b>	0 (0.0)	0 (0.0)	2 (2.9)	>0.99
<b>Plesiomonas</b>	0 (0.0)	1 (4.8)	0 (0.0)	<b>0.293</b>
<b>Helicobacter pylori</b>	2 (25.0)	2 (9.5)	4 (5.7)	0.109
<b>&gt;1 bacteria detected</b>	0 (0.0)	1 (4.8)	14 (20.0)	0.131
<b>Parasite<sup>b</sup></b>	2 (25.0)	8 (38.1)	39 (55.7)	0.145
<b>Cystoisospora</b>	1 (12.5)	4 (19.1)	12 (17.1)	>0.99
<b>Cryptosporidium spp.</b>	0 (0.0)	1 (4.8)	19 (27.1)	<b>0.028</b>
<b>Blastocystis</b>	1 (12.5)	2 (9.5)	5 (7.1)	0.563
<b>Giardia spp.</b>	0 (0.0)	1 (4.8)	4 (5.7)	>0.99
<b>Enterocytozoon spp.</b>	0 (0.0)	1 (4.8)	6 (8.6)	>0.99
<b>Schistosoma</b>	0 (0.0)	0 (0.0)	1 (1.4)	>0.99
<b>&gt;1 parasite detected</b>	0 (0.0)	1 (4.8)	8 (11.4)	0.611
<b>Mixed infections</b>				
<b>Virus-bacteria</b>	1 (12.5)	4 (19.1)	9 (12.9)	0.793
<b>Virus-parasite</b>	1 (12.5)	3 (14.3)	12 (17.1)	>0.99
<b>Bacteria-parasite</b>	2 (25.0)	5 (23.8)	21 (30.0)	0.032

596 <sup>a</sup> CD4+ count within 12 months of enrolment only known for 99 of the 164 HIV-infected cases; <sup>b</sup> The following  
597 parasites were screened for but not detected: *Vibrio cholerae*, *Yersinia enterocolitica*, *E. histolytica*,  
598 *Strongyloides* spp., *Cyclospora*, *Hymenolepis*, *Ascaris*, *Taenia*, *Trichuris*, *Ancylostoma*, *Enterobius*, *Necator*,  
599 *Dientamoeba*.

600 Table S4: Clinical presentation of HIV-infected cases, stratified by treatment

	Antiretroviral treatment <sup>a</sup> - n (%)			Cotrimoxazole prophylaxis <sup>a</sup> - n (%)		
	Yes (n=130)	No (n=26)	p-value	Yes (n=63)	No (n=88)	p-value
Duration of symptoms before admission – median (IQR)	5 (3-8)	4.5 (2-10)	0.489	5 (3-9)	4 (3-8)	0.410
Chronic/persistent diarrhoea	10 (7.7)	3 (11.5)	0.456	6 (9.5)	7 (8.0)	0.774
Weight loss	108 (83.1)	19 (73.1)	0.231	57 (90.5)	67 (76.1)	<b>0.023</b>
Fatigue	98 (75.4)	19 (73.1)	0.804	56 (88.9)	61 (69.3)	<b>0.005</b>
Nausea	92 (70.8)	19 (73.1)	0.813	43 (68.3)	65 (73.9)	0.451
Fever (current or self-reported history in the past 10 days)	89 (68.5)	20 (76.9)	0.391	43 (68.3)	61 (69.3)	0.889
Vomiting	89 (68.5)	22 (84.6)	0.153	42 (66.7)	67 (76.1)	0.200
Abdominal pain	83 (63.9)	18 (69.2)	0.600	42 (66.7)	59 (67.1)	0.961
Respiratory symptoms	59 (45.4)	13 (50.0)	0.667	29 (46.0)	41 (46.6)	0.946
Headache	50 (38.5)	12 (46.2)	0.464	30 (47.6)	33 (37.5)	0.214
Chills	39 (30.0)	6 (23.1)	0.477	32 (50.8)	14 (15.9)	<b>&lt;0.001</b>
Arthralgia	32 (24.6)	2 (7.7)	0.069	13 (20.6)	21 (23.9)	0.640
Dermatological symptoms	21 (16.2)	2 (11.5)	0.768	10 (15.9)	14 (15.9)	0.995
Myalgia	14 (10.8)	1 (3.9)	0.469	10 (15.9)	6 (6.8)	0.075
Dysentery <sup>b</sup>	6 (4.6)	1 (3.9)	>0.99	3 (4.8)	4 (4.6)	>0.99
Neurological symptoms	5 (3.9)	1 (3.9)	>0.99	4 (6.4)	2 (2.3)	0.236
Painful swollen glands	3 (2.3)	0 (0.0)	>0.99	2 (3.2)	1 (1.1)	0.571

601 <sup>a</sup> ART status known for 156 and cotrimoxazole use known for 151 of 164 HIV-infected cases; <sup>b</sup> Dysentery  
602 defined as self-reported blood in the stool.

603

604

605

606

607

608

609

610

611

612

613

614 Table S5: Pathogen detection in specimens of HIV-infected cases, stratified by treatment

	Antiretroviral treatment <sup>a</sup> - n (%)			Cotrimoxazole prophylaxis <sup>a</sup> - n (%)		
	No (n=26)	Yes (n=130)	p-value	No (n=88)	Yes (n=63)	p-value
<b>Any pathogen</b>	23 (88.5)	94 (72.3)	0.082	66 (75.0)	49 (77.8)	0.693
<b>Virus</b>	6 (23.1)	32 (24.6)	0.868	20 (22.7)	16 (25.4)	0.704
<b>Adenovirus</b>	3 (11.5)	14 (10.8)	>0.99	9 (10.2)	8 (12.7)	0.795
<b>Adenovirus 40/41</b>	0 (0.0)	1 (0.8)	>0.99	1(1.1)	0 (0.0)	>0.99
<b>Norovirus</b>	3 (11.5)	10 (7.7)	0.456	6 (6.8)	7 (11.1)	0.354
<b>Norovirus GI</b>	0 (0.0)	1 (0.8)	>0.99	1 (1.1)	0 (0.0)	>0.99
<b>Norovirus GII</b>	3 (11.5)	9 (6.9)	0.423	5 (5.7)	7 (11.1)	0.240
<b>Enterovirus</b>	1 (3.9)	8 (6.2)	>0.99	4 (4.6)	4 (6.4)	0.720
<b>CMV</b>	0 (0.0)	3 (2.3)	>0.99	2 (2.3)	1 (1.6)	>0.99
<b>Astrovirus</b>	0 (0.0)	3 (2.3)	>0.99	0 (0.0)	2 (3.2)	0.172
<b>Rotavirus</b>	0 (0.0)	1 (0.8)	>0.99	0 (0.0)	1 (1.6)	0.417
<b>Sapovirus</b>	0 (0.0)	0 (0.0)	-	0 (0.0)	0 (0.0)	-
<b>&gt;1 virus detected</b>	1 (3.9)	5 (3.9)	>0.99	1 (1.1)	5 (7.9)	0.083
<b>Bacteria</b>	16 (61.5)	62 (47.7)	0.197	44 (50.0)	32 (50.8)	0.923
<b>Shigella spp.</b>	5 (19.2)	24 (18.5)	>0.99	18 (20.5)	9 (14.3)	0.329
<b>Salmonella spp.</b>	2 (7.7)	10 (7.7)	>0.99	6 (6.8)	5 (7.9)	>0.99
<b>C. difficile</b>	2 (7.7)	10 (7.7)	>0.99	6 (6.8)	6 (9.5)	0.544
<b>Campylobacter</b>	1 (3.9)	10 (7.7)	0.692	4 (4.6)	7 (11.1)	0.202
<b>STEC</b>	0 (0.0)	0 (0.0)	-	0 (0.0)	0 (0.0)	-
<b>ETEC</b>	1 (3.9)	3 (2.3)	0.522	3 (3.4)	1 (1.6)	0.641
<b>EPEC</b>	2 (7.7)	8 (6.2)	0.673	6 (6.8)	5 (7.9)	>0.99
<b>EAEC</b>	2 (7.7)	18 (13.9)	0.531	10 (11.4)	8 (12.7)	0.803
<b>O157</b>	0 (0.0)	3 (2.3)	>0.99	1 (1.1)	2 (3.2)	0.571
<b>Plesiomonas</b>	0 (0.0)	1 (0.8)	>0.99	0 (0.0)	1 (1.6)	0.417
<b>Helicobacter pylori</b>	4 (15.4)	8 (6.2)	0.117	6 (6.8)	6 (9.5)	0.544
<b>&gt;1 bacteria detected</b>	2 (7.7)	24 (18.5)	0.252	11 (12.5)	13 (20.6)	0.178
<b>Parasite<sup>b</sup></b>	12 (46.2)	59 (45.4)	>0.99	33 (37.5)	37 (58.7)	<b>0.010</b>
<b>Cystoisospora</b>	4 (15.4)	24 (18.5)	>0.99	10 (11.4)	17 (26.9)	<b>0.014</b>
<b>Cryptosporidium spp.</b>	5 (19.2)	21 (16.2)	0.773	12 (13.6)	14 (22.2)	0.168
<b>Blastocystis</b>	4 (15.4)	6 (4.6)	0.063	8 (9.1)	2 (3.2)	0.195
<b>Giardia spp.</b>	1 (3.9)	5 (3.9)	>0.99	4 (4.6)	2 (3.2)	>0.99
<b>Enterocytozoon spp.</b>	0 (0.0)	10 (7.7)	0.215	4 (4.6)	6 (9.5)	0.321
<b>Schistosoma</b>	0 (0.0)	4 (3.1)	>0.99	3 (3.4)	1 (1.6)	0.641
<b>&gt;1 parasite detected</b>	2 (7.7)	10 (7.7)	>0.99	7 (8.0)	5 (7.9)	>0.99
<b>Mixed infections</b>						
<b>Virus-bacteria</b>	3 (11.5)	20 (15.4)	0.768	11 (12.5)	11 (17.5)	0.394
<b>Virus-parasite</b>	2 (7.7)	19 (14.6)	0.531	8 (9.1)	11 (17.5)	0.126




<b>Bacteria- parasite</b>	8 (30.8)	34 (26.2)	0.633	19 (21.6)	22 (34.9)	0.069
-------------------------------	----------	-----------	-------	-----------	-----------	-------

615 <sup>a</sup> ART status known for 156 and cotrimoxazole use known for 151 of 164 HIV-infected cases; <sup>b</sup> The following  
616 parasites were screened for but not detected: *E. histolytica*, *Strongyloides* spp., *Cyclospora*, *Hymenolepis*,  
617 *Ascaris*, *Taenia*, *Trichuris*, *Ancylostoma*, *Enterobius*, *Necator*, *Dientamoeba*.

618

619



medRxiv preprint doi: <https://doi.org/10.1101/2023.02.23.23286353>; this version posted February 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](#).

<sup>a</sup> Due to limited TAC tests available, cases with unknown HIV status were excluded from the analysis. Controls with unknown HIV status were included to increase sample size for the overall case-control analysis, but were not included in the HIV specific analysis.

**Figure 1: Specimens included in the analysis**